描述(Description)
The HEK293/Human LRRC15 Stable Cell Line was engineered to express the receptor full length human LRRC15 (Gene ID: 131578), used to mimic cancer target cells. Surface expression of human LRRC15 was confirmed by flow cytometry.
应用说明(Application)
• Useful for cell-based LRRC15 binding assay
生长特性(Growth Properties)
Adherent
筛选标记(Selection Marker)
Puromycin (2 μg/mL)
培养基(Culture Medium)
DMEM + 10% FBS
冻存液(Freeze Medium)
Serum-free cell cryopreservation medium
装量(Quantity)
1 vial contains at least 5×10^6 cells in 1 mL serum-free cryopreservation medium
存储(Storage)
Frozen in liquid nitrogen.
支原体检测(Mycoplasma Testing)
Negative
无菌检测(Sterility Testing)
Negative
使用说明(Instructions for Use)
See data sheet for detailed culturing and assay protocol.
活性(Bioactivity)
Expression analysis of human LRRC15 on HEK293/Human LRRC15 Stable Cell Line by FACS.
Cell surface staining was performed on HEK293/Human LRRC15 Stable Cell Line or negative control cell using anti-human LRRC15 antibody followed by staining with FITC anti-mouse IgG antibody.
Protocol
如有相关细胞池需求请联系我们
背景(Background)
LRRC15 (Leucine-rich repeat-containing protein 15) is also known as LIB and hLib. LRRC15 is highly expressed in a variety of solid tumors. LRRC15 was expressed on stromal fibroblasts in many solid tumors (e.g., breast, head and neck, lung, pancreatic) as well as directly on a subset of cancer cells of mesenchymal origin (e.g., sarcoma, melanoma, glioblastoma). LRRC15 expression was induced by TGFβ on activated fibroblasts (αSMA+) and on mesenchymal stem cells. These collective findings suggested LRRC15 as a novel CAF and mesenchymal marker with utility as a therapeutic target for the treatment of cancers with LRRC15-positive stromal desmoplasia or cancers of mesenchymal origin. ABBV-085 is a monomethyl auristatin E (MMAE)-containing antibody–drug conjugate (ADC) directed against LRRC15, and it demonstrated robust preclinical efficacy against LRRC15 stromal-positive/cancer-negative, and LRRC15 cancer-positive models as a monotherapy, or in combination with standard-of-care therapies.
License Disclosure
This cell line is provided for research use only. This license does not permit you to share, distribute, sell, sublicense, or otherwise make this cell line available for use to other laboratories, departments, research institutions, hospitals, universities, or biotech companies. The license does not permit modification of this cell line in any way. Inappropriate use or distribution of this cell line will result in revocation of the license. Modifications of this cell line, transfer to another facility, or commercial use of the cell lines may require a separate license and additional fees. AcroBiosystems does not warrant the suitability of this cell line for any particular use, and does not accept any liability in connection with the handling or use of this cell line.